Eris Lifesciences Q2 Results 2025 Highlights: Net Profit Rises 31.14% & Revenue Up 6.91% YoY

Click and Sign Up to Get Live Updates on Q2 Results 

Eris Lifesciences Q2 Results FY26: During Q2 FY26, Eris Lifesciences’ profit increased 31.14% YoY, while revenue increased by 6.91% YoY. The company posted robust numbers, with Q2 PAT at ₹120.19 crores and revenue at ₹792.41 crores. Eris Lifesciences announced its Q2 results on 12th November 2025.  

Eris Lifesciences Q2 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

Eris Lifesciences Q2 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Eris Lifesciences Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

• Eris Lifesciences reported Q2 FY26 consolidated revenue of ₹792.41 crores, down from ₹741.17 crores. 
• On the profit front, Eris Lifesciences earned a consolidated PAT of ₹120.19 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹91.65 crore.
• According to the consolidated figures, Eris Lifesciences’ quarterly PAT increased by 31.14% YoY, while revenue increased by 6.91%.
• Eris Lifesciences reported Q2 FY26 standalone revenue of ₹650.5 crores, down from ₹436.56 crores. 
• On the profit front, Eris Lifesciences earned a standalone PAT of ₹149.57 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹28.1 crore.
• According to the standalone figures, Eris Lifesciences’ quarterly PAT increased by 432.28% YoY, while revenue increased by 49.01%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Eris Lifesciences Share Price Performance

On the opening bell on 18th November 2025, Eris Lifesciences shares opened at ₹1,572 per share. However, the initial gains have since eroded, and Eris Lifesciences shares are currently trading at ₹1,567.90 per share, which is lower than the opening price.    

Considering the long-term achievements, Eris Lifesciences shares have yielded returns of approximately 8.60% over the past 6 months, and 1-year returns stand at 15.85%. Over the maximum timeframe, Eris Lifesciences shares delivered a return of 160.75% to investors. 

What Analysts Expect Post Q2 Results?

Following Eris Lifesciences’ robust Q2 results, analysts expect its share price to rise. According to analysts, Eris Lifesciences’ share price is expected to reach ₹2,050 per share in the coming year; however, in a downturn, it could fall to ₹967 per share. However, one must ignore stock market volatility and invest in Eris Lifesciences’ shares after thorough research. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here